ST3Gal1 is also enrolled in promoting resistance to anti-cancer effects of agents, such as of adriamycin directed against chronic myeloid leukemia (CML) cell lines (73), paclitaxel against ovarian cancer cells (70), and tamoxifen and/or vandetanib against breast cancer cells (66). This evidence concerns the gene ST3GAL1 and ovarian carcinoma.